NEUROCRINE BIOSCIENCES INC Sales Revenue, Goods, Net (Deprecated 2018-01-31)
NEUROCRINE BIOSCIENCES INC (NBIX) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $71.09 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-04-30.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-04-30
- NEUROCRINE BIOSCIENCES INC sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $71.09M.
- NEUROCRINE BIOSCIENCES INC sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $64.52M.
- NEUROCRINE BIOSCIENCES INC sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $45.77M.
- NEUROCRINE BIOSCIENCES INC sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $6.33M.
- NEUROCRINE BIOSCIENCES INC sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $116.63M.
- NEUROCRINE BIOSCIENCES INC sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $0.00.
- NEUROCRINE BIOSCIENCES INC sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $0.00.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $71.09M 10-Q · filed 2018-04-30 | $135.60M derived: sum of 2 quarters · filed 2018-04-30 | $181.38M derived: sum of 3 quarters · filed 2018-04-30 | $187.71M derived: sum of 4 quarters · filed 2018-04-30 |
| 2017-12-31 | $64.52M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $110.29M derived: sum of 2 quarters · filed 2018-02-13 | $116.63M derived: sum of 3 quarters · filed 2018-02-13 | $116.63M 10-K · filed 2018-02-13 |
| 2017-09-30 | $45.77M 10-Q · filed 2017-11-01 | $52.11M derived: sum of 2 quarters · filed 2017-11-01 | $52.11M 10-Q · filed 2017-11-01 | $52.11M derived: sum of 4 quarters · filed 2018-04-30 |
| 2017-06-30 | $6.33M 10-Q · filed 2017-08-03 | $6.33M 10-Q · filed 2017-08-03 | $6.33M derived: sum of 3 quarters · filed 2018-04-30 | $6.33M derived: sum of 4 quarters · filed 2018-04-30 |
| 2017-03-31 | $0.00 10-Q · filed 2018-04-30 | $0.00 derived: sum of 2 quarters · filed 2018-04-30 | $0.00 derived: sum of 3 quarters · filed 2018-04-30 | $0.00 derived: sum of 4 quarters · filed 2018-04-30 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $0.00 derived: sum of 2 quarters · filed 2018-02-13 | $0.00 derived: sum of 3 quarters · filed 2018-02-13 | $0.00 10-K · filed 2018-02-13 |
| 2016-09-30 | $0.00 10-Q · filed 2017-11-01 | $0.00 derived: sum of 2 quarters · filed 2017-11-01 | $0.00 10-Q · filed 2017-11-01 | |
| 2016-06-30 | $0.00 10-Q · filed 2017-08-03 | $0.00 10-Q · filed 2017-08-03 | ||
| 2015-12-31 | $0.00 10-K · filed 2018-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |